Literature DB >> 11505062

Proliferative activity in Barrett's esophagus before and after antireflux surgery.

L Q Chen1, C Y Hu, L Gaboury, M Pera, P Ferraro, A C Duranceau.   

Abstract

OBJECTIVE: To assess proliferation in the columnar-lined esophageal mucosa before and after antireflux surgery. SUMMARY BACKGROUND DATA: Intestinal metaplasia persists in Barrett's mucosa after reflux control. It remains at risk for uncontrolled cellular proliferation and adenocarcinoma formation.
METHODS: Forty-five patients with Barrett's esophagus had a mean follow-up of 4 years after a Collis-Nissen gastroplasty. Proliferative activity was assayed immunohistochemically for Ki-67 expression in 73 preoperative and 176 postoperative biopsies. Correlation with manometric and 24-hour pH results was obtained.
RESULTS: The Collis-Nissen gastroplasty restored the median lower esophageal sphincter gradient from 5.5 mmHg before surgery to 14.5 mmHg at 24 months and 12.9 mmHg at 48 months after surgery. The median esophageal acid exposure was reduced from 8% to 1% and 1% of recording time, respectively. The median Ki-67 labeling index increased from 28.5% before surgery to 36.1% at 12 to 23 months. It returned to preoperative level (26.9%) at 24 to 47 months. After surgery, abnormal intraesophageal acid exposure was documented in 12 patients but could not be correlated with sphincter pressure. After surgery, the pattern of proliferation in patients with acid exposure less than 4% in their esophagus showed significant differences when compared with the proliferation pattern of patients where abnormal intraesophageal acid exposure was recorded. New present dysplasia was observed only in patients with abnormal acid exposure.
CONCLUSIONS: In Barrett's mucosa, from preoperative values, proliferation peaked early after surgery and then decreased to preoperative levels. Despite sphincter restoration and global reflux control, abnormal esophageal acid exposure persisted in 12 patients. Patients with abnormal esophageal acid exposure displayed more proliferation and more dysplasia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505062      PMCID: PMC1422003          DOI: 10.1097/00000658-200108000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  46 in total

1.  Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.

Authors:  R Ouatu-Lascar; G Triadafilopoulos
Journal:  Am J Gastroenterol       Date:  1998-05       Impact factor: 10.864

2.  Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.

Authors:  R C Fitzgerald; M B Omary; G Triadafilopoulos
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Gastroesophageal reflux in achalasia. When is reflux really reflux?

Authors:  P F Crookes; S Corkill; T R DeMeester
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

4.  Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.

Authors:  S P Singh; J Lipman; H Goldman; F H Ellis; L Aizenman; M G Cangi; S Signoretti; D S Chiaur; M Pagano; M Loda
Journal:  Cancer Res       Date:  1998-04-15       Impact factor: 12.701

5.  The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.

Authors:  D Katz; R Rothstein; A Schned; J Dunn; K Seaver; D Antonioli
Journal:  Am J Gastroenterol       Date:  1998-04       Impact factor: 10.864

6.  Squamous islands in Barrett's esophagus: what lies underneath?

Authors:  P Sharma; T G Morales; A Bhattacharyya; H S Garewal; R E Sampliner
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

7.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

8.  Normal patterns of acid exposure at the gastric cardia: a functional midpoint between the esophagus and stomach.

Authors:  D A Katzka; R M Gideon; D O Castell
Journal:  Am J Gastroenterol       Date:  1998-08       Impact factor: 10.864

9.  Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.

Authors:  H J Stein; W K Kauer; H Feussner; J R Siewert
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

10.  A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa.

Authors:  M Bromley; D Rew; A Becciolini; M Balzi; C Chadwick; D Hewitt; Y Q Li; C S Potten
Journal:  Eur J Histochem       Date:  1996       Impact factor: 3.188

View more
  5 in total

1.  Is symptom control the correct end point for proton pump inhibitor treatment in Barrett's oesophagus?

Authors:  A I Sarela; C S Verbeke; C Pring; P J Guillou
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Short esophagus: selection of patients for surgery and long-term results.

Authors:  Luis Durand; Roberto De Antón; Miguel Caracoche; Enrique Covián; Mariano Gimenez; Pedro Ferraina; Lee Swanström
Journal:  Surg Endosc       Date:  2011-10-15       Impact factor: 4.584

Review 3.  The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.

Authors:  Eugene Y Chang; Cynthia D Morris; Ann K Seltman; Robert W O'Rourke; Benjamin K Chan; John G Hunter; Blair A Jobe
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

4.  Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.

Authors:  Benjamin A Onwuegbusi; Jonathan R E Rees; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  PLoS One       Date:  2007-01-31       Impact factor: 3.240

5.  Ki-67 Antigen Overexpression Is Associated with the Metaplasia-Adenocarcinoma Sequence in Barrett's Esophagus.

Authors:  Bernardo Silveira Volkweis; Richard Ricachenevsky Gurski; Luise Meurer; Guilherme Gonçalves Pretto; Guilherme da Silva Mazzini; Maria Isabel Edelweiss
Journal:  Gastroenterol Res Pract       Date:  2012-07-11       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.